Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
AKBA Akebia Therapeutics, Inc. daily Stock Chart
AKBA [NASD]
Akebia Therapeutics, Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E- EPS (ttm)-1.28 Insider Own0.90% Shs Outstand52.22M Perf Week-1.65%
Market Cap403.66M Forward P/E- EPS next Y-1.88 Insider Trans0.00% Shs Float47.71M Perf Month-11.35%
Income-71.30M PEG- EPS next Q-0.43 Inst Own67.40% Short Float9.40% Perf Quarter-1.28%
Sales235.20M P/S1.72 EPS this Y50.90% Inst Trans-8.46% Short Ratio8.91 Perf Half Y-25.10%
Book/sh2.50 P/B3.09 EPS next Y12.40% ROA-17.50% Target Price18.63 Perf Year-50.10%
Cash/sh7.47 P/C1.03 EPS next 5Y- ROE-45.40% 52W Range7.32 - 16.43 Perf YTD-48.02%
Dividend- P/FCF- EPS past 5Y-22.90% ROI-65.20% 52W High-52.95% Beta1.13
Dividend %- Quick Ratio2.20 Sales past 5Y- Gross Margin- 52W Low5.60% ATR0.63
Employees114 Current Ratio2.20 Sales Q/Q28.80% Oper. Margin-32.60% RSI (14)46.12 Volatility10.71% 7.37%
OptionableYes Debt/Eq0.00 EPS Q/Q7.30% Profit Margin-30.30% Rel Volume1.48 Prev Close8.96
ShortableYes LT Debt/Eq0.00 EarningsNov 14 AMC Payout- Avg Volume503.57K Price7.73
Recom2.10 SMA20-5.39% SMA50-5.87% SMA200-23.98% Volume747,316 Change-13.73%
Sep-07-18Resumed Morgan Stanley Equal-Weight
Aug-10-18Reiterated Needham Buy $20 → $18
Jun-06-18Reiterated H.C. Wainwright Buy $24 → $22
Dec-19-17Initiated Piper Jaffray Overweight $26
Dec-07-17Initiated BTIG Research Buy $30
Sep-15-17Initiated RBC Capital Mkts Sector Perform $17
Jul-10-17Reiterated H.C. Wainwright Buy $25 → $24
Apr-27-17Reiterated Needham Buy $14 → $18
Apr-27-17Reiterated H.C. Wainwright Buy $18 → $21
Dec-27-16Reiterated H.C. Wainwright Buy $17 → $18
Dec-20-16Reiterated JMP Securities Mkt Outperform $16 → $19
Nov-15-16Initiated Aegis Capital Buy
Sep-29-16Initiated Brean Capital Buy
Mar-16-16Reiterated Needham Buy $18 → $14
Jan-21-16Initiated Credit Suisse Neutral
Dec-15-15Reiterated Needham Buy $14 → $18
Dec-15-15Reiterated H.C. Wainwright Buy $24 → $25
Dec-07-15Initiated H.C. Wainwright Buy $24
Sep-09-15Upgrade Morgan Stanley Equal-Weight → Overweight
Aug-13-15Initiated Morgan Stanley Equal-Weight $10
Nov-08-18 05:40PM  Akebia Therapeutics (AKBA) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:36PM  Akebia Therapeutics: 3Q Earnings Snapshot Associated Press
04:30PM  Akebia Therapeutics Announces Third Quarter 2018 Financial Results Business Wire
Nov-07-18 10:30AM  Analysts Estimate Akebia Therapeutics (AKBA) to Report a Decline in Earnings: What to Look Out for Zacks +8.41%
Nov-02-18 04:05PM  Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Oct-30-18 05:35PM  Akebia Therapeutics Files Definitive Proxy Statement in Connection with Proposed Merger with Keryx Biopharmaceuticals Business Wire
05:31PM  Keryx Biopharmaceuticals Announces Filing of Definitive Joint Proxy Statement in Connection with Pending Merger with Akebia Therapeutics GlobeNewswire
Oct-19-18 09:25AM  Report: Developing Opportunities within VICI Properties, Transocean, Akebia Therapeutics, Welltower, Golden Star Resources, and Casa Future Expectations, Projections Moving into 2018 GlobeNewswire
Oct-09-18 04:05PM  Akebia Therapeutics Announces Presentations at the American Society of Nephrology Kidney Week 2018 Annual Meeting Business Wire
Oct-02-18 04:05PM  Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Oct-01-18 11:38AM  Endo Recalls 2 Lots of Robaxin Tablets Due to Labeling Error Zacks
Sep-25-18 04:05PM  Akebia Therapeutics to Participate in Upcoming Investor Conferences Business Wire
Sep-14-18 11:19AM  What Investors Should Know About Akebia Therapeutics Incs (NASDAQ:AKBA) Financial Strength Simply Wall St.
Sep-04-18 04:05PM  Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Aug-30-18 04:05PM  Akebia Therapeutics to Participate in Upcoming Investor Conferences Business Wire
Aug-29-18 11:52AM  5 Healthcare Stocks That Are Down, But Not Out! InvestorPlace
Aug-28-18 04:05PM  Akebia Therapeutics Appoints Cynthia Smith to Its Board of Directors Business Wire
Aug-21-18 08:30AM  Report: Exploring Fundamental Drivers Behind Oaktree Specialty Lending, uniQure N.V, Mercury, Akebia Therapeutics, Mitel Networks, and Greenlight Capital Re New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Aug-19-18 09:45PM  Edited Transcript of AKBA earnings conference call or presentation 8-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-09-18 11:57AM  Keryx's (KERX) Loss Wider Than Expected in Q2, Sales Lag Zacks -15.43%
08:39AM  The Daily Biotech Pulse: Ampio Slides On Offering, Sangamo's Positive Trial Results, Insys Earnings Benzinga
Aug-08-18 07:25PM  Akebia Therapeutics (AKBA) Reports Q2 Loss, Tops Revenue Estimates Zacks
06:19PM  Akebia Therapeutics: 2Q Earnings Snapshot Associated Press
04:05PM  Akebia Therapeutics Announces Second Quarter 2018 Financial Results Business Wire
02:30PM  Akebia Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-02-18 04:05PM  Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Aug-01-18 04:05PM  Akebia Therapeutics to Host Second Quarter 2018 Investor Update Call and Webcast Business Wire
Jul-30-18 02:00PM  7 Health Care Stocks to Buy for Robust Returns Kiplinger
Jul-06-18 03:07PM  INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Keryx Biopharmaceuticals, Inc. to Akebia Therapeutics, Inc. is Fair to Shareholders GlobeNewswire
Jul-05-18 06:17PM  Biotech Stock Roundup: GILD's Positive CHMP Nod, Regulatory Updates & More Zacks
Jul-02-18 04:05PM  Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Jun-29-18 07:12PM  WeissLaw LLP Investigates Keryx Biopharmaceuticals Inc. PR Newswire +6.62%
09:08AM  Keryx (KERX) Inks Merger Deal With Akebia, Shares Fall Zacks
Jun-28-18 11:21AM  Here's Why Keryx Biopharmaceuticals and Akebia Therapeutics Are Plunging Today Motley Fool -9.83%
07:00AM  Akebia Therapeutics and Keryx Biopharmaceuticals to Merge, Creating a Fully Integrated Company Focused on the Development and Commercialization of Therapeutics for Patients with Kidney Disease Business Wire
Jun-26-18 07:51PM  Ex-Akebia employee jailed for night as insider trading trial starts Reuters
04:02PM  Ex-Akebia employee jailed for night as insider trading trial starts Reuters
Jun-11-18 07:40AM  Todays Free Research Reports Coverage on Agenus and Three More Biotech Stocks ACCESSWIRE
Jun-06-18 08:10AM  Investor Expectations to Drive Momentum within Core-Mark Holding, SSR Mining, iRhythm Technologies, Magic Software Enterprises, Jounce Therapeutics, and Akebia Therapeutics Discovering Underlying Factors of Influence GlobeNewswire +5.09%
Jun-04-18 04:05PM  Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
May-15-18 04:05PM  Akebia Therapeutics to Present at Upcoming Investor Conference Business Wire
May-09-18 05:16PM  Akebia Therapeutics: 1Q Earnings Snapshot Associated Press
May-02-18 04:05PM  Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Apr-09-18 07:50AM  Research Report Identifies Yirendai, Atlantic Capital Bancshares, Jazz Pharmaceuticals, Sina, Akebia Therapeutics, and SMART Global with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Apr-03-18 04:05PM  Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Mar-23-18 08:00AM  Akebia Therapeutics Announces Pricing of Public Offering of Common Stock Business Wire -10.19%
Mar-22-18 04:26PM  Akebia Therapeutics Announces Proposed Public Offering of Common Stock Business Wire
Mar-21-18 08:30AM  Akebia Therapeutics to Present at Upcoming Investor Conferences Business Wire
Mar-20-18 07:40AM  Blog Exposure - Chiasma to Present Design of Phase-3 Double-Blind Trial of Oral Octreotide Capsules Versus Placebo in Acromegaly Patients at ENDO 2018 ACCESSWIRE
Mar-16-18 08:30AM  New Research: Key Drivers of Growth for CNB Financial, Akebia Therapeutics, Mesoblast, 21Vianet Group, Old Line Bancshares, and BioSpecifics Technologies Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Mar-13-18 01:11PM  Edited Transcript of AKBA earnings conference call or presentation 12-Mar-18 8:30pm GMT Thomson Reuters StreetEvents -6.88%
Mar-12-18 04:29PM  Akebia Therapeutics posts 4Q profit Associated Press
04:03PM  Akebia Therapeutics Announces Fourth Quarter and Full-Year 2017 Financial Results Business Wire
01:15PM  Akebia Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Mar-05-18 08:30AM  Akebia Therapeutics to Host Fourth Quarter and Full-Year 2017 Investor Update Call and Webcast Business Wire
Mar-02-18 04:05PM  Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Feb-12-18 07:00AM  Akebia Therapeutics Provides Update on Vadadustat Development Program Business Wire
Feb-08-18 08:00AM  Akebia Therapeutics to Present at Upcoming February Investor Conferences Business Wire
Feb-02-18 04:30PM  Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Jan-04-18 07:00AM  Akebia Therapeutics Announces Positive Top-Line Results from Phase 2 Study of Vadadustat in Japanese Patients with Anemia Associated with Dialysis-Dependent Chronic Kidney Disease Business Wire
Jan-02-18 04:05PM  Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Dec-13-17 08:44AM  Market Has Not Yet Noticed Potential in Akebia Therapeutics (AKBA); Have You? Zacks
Dec-07-17 08:46AM  Falling Earnings Estimates Signal Weakness Ahead for Aerie Pharmaceuticals (AERI) Zacks
Dec-06-17 09:07AM  The Zacks Analyst Blog Highlights: Sangamo Therapeutics, Sarepta Therapeutics, Akebia Therapeutics, Calithera Biosciences and GlycoMimetics Zacks
Dec-05-17 08:09AM  5 Top-Ranked Drug Stocks that are Broker Favorites Zacks
Dec-04-17 08:52AM  Concert Pharmaceuticals (CNCE) Soars: Stock Adds 5.7% in Session Zacks
Dec-01-17 04:05PM  Akebia Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Nov-28-17 08:36AM  GlycoMimetics (GLYC) Jumps: Stock Rises 11.9% Zacks
Nov-16-17 08:00AM  Akebia Therapeutics to Participate in Upcoming Investor Conferences Business Wire
Nov-14-17 12:25PM  Newly public Cincinnati firm names new CFO American City Business Journals -5.51%
Nov-08-17 05:33PM  Akebia Therapeutics reports 3Q loss Associated Press
04:05PM  Akebia Therapeutics Announces Third Quarter 2017 Financial Results Business Wire
Nov-07-17 12:33PM  Is Akebia Therapeutics Incs (AKBA) Liquidity As Good As Its Solvency? Simply Wall St.
Nov-03-17 04:05PM  Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Oct-27-17 11:29AM  Akebia Therapeutics, Inc. Value Analysis (NASDAQ:AKBA) : October 27, 2017 Capital Cube
Oct-26-17 08:20AM  Akebia Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : AKBA-US : October 26, 2017 Capital Cube
Oct-04-17 04:05PM  Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Sep-26-17 04:26PM  Axovant Shares Plummet On Alzheimer's Data; Genocea Gets Rocked -Biotech Movers TheStreet.com
07:00AM  Akebia Announces Positive Top-Line Results from Phase 2 Study of Vadadustat in Japanese Patients with Non-Dialysis-Dependent Chronic Kidney Disease Business Wire
Sep-22-17 05:33PM  Ex-Akebia employee suspected of insider trading re-arrested Reuters
05:27PM  Ex-Akebia employee suspected of insider trading re-arrested Reuters
Sep-08-17 08:35AM  Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Sep-07-17 01:24PM  BioMarin Presents Interim Data on BMN 250 from Phase I/II Zacks
Sep-05-17 08:42AM  Why Akebia Therapeutics (AKBA) Could Be Positioned for a Surge Zacks
08:30AM  Akebia to Present at Upcoming Investor Conferences Business Wire
Aug-23-17 07:10AM  Featured Company News - ContraVir Announces Issuance of New US Patent for Expansion of Cyclophilin Inhibitor Program ACCESSWIRE
Aug-14-17 08:27AM  Akebia Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : AKBA-US : August 14, 2017 Capital Cube
Aug-08-17 11:04PM  Akebia Therapeutics reports 2Q loss Associated Press
04:05PM  Akebia Announces Second Quarter 2017 Financial Results Business Wire
Aug-04-17 04:05PM  Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Jul-24-17 01:53PM  ETFs with exposure to Akebia Therapeutics, Inc. : July 24, 2017 Capital Cube
Jul-20-17 05:08PM  Ex-Akebia employee faces losing bail in insider trading case Reuters
Jul-14-17 12:41PM  ETFs with exposure to Akebia Therapeutics, Inc. : July 14, 2017 Capital Cube
Jul-12-17 03:09PM  Akebia Therapeutics, Inc. Value Analysis (NASDAQ:AKBA) : July 12, 2017 Capital Cube
Jul-11-17 09:15AM  Akebia Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : AKBA-US : July 11, 2017 Capital Cube
Jul-06-17 07:00AM  Akebia Announces Closing of Public Offering of Common Stock and Exercise of Option by Underwriters Business Wire
Jun-29-17 09:26AM  Biotech Movers: Akebia Shares Down After Pricing Stock Offering TheStreet.com
Jun-28-17 10:46PM  Akebia Announces Pricing of Public Offering of Common Stock Business Wire
04:15PM  Akebia Therapeutics Announces Proposed Public Offering of Common Stock Business Wire
Jun-20-17 07:00AM  Akebia Therapeutics to Host Analyst and Investor Day on June 27, 2017 Business Wire
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for patients with renal disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease in dialysis and non-dialysis patients. The company is also developing a HIF-based portfolio of product candidates, such as AKB-5169, a preclinical compound for the treatment of inflammatory bowel disease. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of HIF-prolyl hydroxylases-targeted compounds internationally. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Butler John P.CEO and PresidentJul 11Option Exercise0.47100,00047,000510,314Jul 12 04:59 PM
Nash DuaneDirectorFeb 15Sale14.621,00014,62021,499Feb 16 04:07 PM
open in yahoo | open in reuters | open in google